Impact of fetal nicotine exposure on development of rat brain regions: critical sensitive periods or effects of withdrawal?
Fetal nicotine exposure evokes alterations in central nervous system structural, neurochemical, and behavioral development. In the current study, the relative importance of critical developmental exposure periods and withdrawal were examined by infusing nicotine to pregnant rats using osmotic minipumps beginning on the fourth day of gestation. Infusions were confined to either the first 8 days (withdrawal on gestational day 13), to nearly all of gestation (withdrawal on gestational day 21), or throughout gestation and continued into the first 2 postnatal weeks. Maternal weight gain was retarded by nicotine, with a hierarchy corresponding to the duration of nicotine exposure. Similarly, fetal and neonatal body weights were unaffected in the group receiving the shortest duration of nicotine exposure, and were less affected by the intermediate infusion regimen than by the longest regimen; brain region weights were reduced significantly only with the longest regimen. Using ODC activity, a sensitive marker for altered brain cell development, we found little change in animals exposed to nicotine in early gestation and undergoing withdrawal on day 13. However, in the groups receiving nicotine through the end of gestation or through gestation and into the postnatal period, ODC activity was significantly elevated. These results indicate that withdrawal from nicotine contributes little, if any, effect either to the growth deficits or to abnormalities of brain cell development. Instead, the most important factor appears to be exposure within the developmental period corresponding to the proliferation of nicotinic receptors and the timing of receptor control of cell replication and differentiation.
Slotkin
T A
TA
Department of Pharmacology, Duke University Medical Center, Durham, NC 27710.
Lappi
S E
SE
Seidler
F J
FJ
D000818:Animals; D000831:Animals, Newborn / Q000502:physiology; D001724:Birth Weight / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000201:enzymology / Q000254:growth & development*; D002454:Cell Differentiation / Q000502:physiology; D002455:Cell Division / Q000502:physiology; D003712:Dendrites / Q000502:physiology; D005260:Female; D008566:Membranes / Q000187:drug effects / Q000378:metabolism; D009538:Nicotine / Q000633:toxicity*; D009929:Organ Size / Q000187:drug effects; D009955:Ornithine Decarboxylase / Q000378:metabolism; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D011978:Receptors, Nicotinic / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000201:enzymology / Q000503:physiopathology*
D011978:Receptors, Nicotinic; D009538:Nicotine; D009955:Ornithine Decarboxylase